#1 Clinical Trials Search in Europe

Fenebrutinib

Fenebrutinib is an investigational drug currently being studied in clinical trials for its potential to treat multiple sclerosis (MS), particularly relapsing and primary progressive forms of the disease. These trials aim to evaluate the efficacy, safety, and pharmacokinetics of fenebrutinib compared to existing treatments and placebos. The studies involve various measurements, including brain lesions, disability progression, and patient-reported outcomes, to assess the drug’s impact on MS symptoms and disease progression.

Table of Contents

What is Fenebrutinib?

Fenebrutinib, also known by its research code RO7010939, is a new medication being studied for the treatment of multiple sclerosis (MS)[1]. It belongs to a class of drugs called Bruton’s tyrosine kinase (BTK) inhibitors, which are designed to reduce inflammation in the body[2].

How Fenebrutinib Works

Fenebrutinib works by targeting and blocking a specific enzyme in the body called Bruton’s tyrosine kinase. This enzyme plays a crucial role in the activation of certain immune cells that contribute to inflammation in MS. By inhibiting this enzyme, fenebrutinib aims to reduce the inflammatory processes that cause damage to the nervous system in MS patients[2].

Conditions Treated by Fenebrutinib

Fenebrutinib is being studied for the treatment of two main types of multiple sclerosis:

  • Relapsing Multiple Sclerosis (RMS): This is the most common form of MS, characterized by periods of new or worsening symptoms (relapses) followed by periods of recovery (remissions)[2][3].
  • Primary Progressive Multiple Sclerosis (PPMS): This is a less common form of MS where symptoms steadily worsen over time without distinct relapses or remissions[5].

Clinical Trials and Research

Several clinical trials are currently underway to evaluate the effectiveness and safety of fenebrutinib in treating multiple sclerosis:

  • Phase III trials for Relapsing Multiple Sclerosis: These large-scale studies are comparing fenebrutinib to an existing MS medication called teriflunomide. Researchers are measuring how well fenebrutinib reduces relapse rates and slows disability progression compared to teriflunomide[3][4].
  • Phase III trial for Primary Progressive Multiple Sclerosis: This study is comparing fenebrutinib to another MS medication called ocrelizumab in patients with PPMS. The main goal is to see if fenebrutinib can slow down disability progression better than ocrelizumab[5].
  • Brain lesion studies: Researchers are using magnetic resonance imaging (MRI) to measure how fenebrutinib affects the number and size of brain lesions in MS patients. These lesions are areas of damage in the brain caused by MS[2].

How Fenebrutinib is Administered

Fenebrutinib is taken orally, which means it’s given as a pill or liquid that patients can take by mouth. This is different from some other MS medications that require injections or intravenous infusions. The exact dosage and frequency of administration are still being determined through clinical trials[1][2].

Safety and Side Effects

As with any medication, researchers are closely monitoring the safety of fenebrutinib and any potential side effects. Some of the aspects being studied include:

  • Adverse events (AEs): These are any undesirable experiences associated with the use of the medication[2][3].
  • Serious adverse events (SAEs): These are more severe side effects that may require medical intervention[2][3].
  • Changes in vital signs and laboratory results: Researchers are monitoring how fenebrutinib affects things like blood pressure, heart rate, and various blood tests[1].
  • Suicidal thoughts or behaviors: As with many medications that affect the nervous system, researchers are carefully monitoring for any impact on mental health[2].

It’s important to note that as fenebrutinib is still in the research phase, a complete understanding of its side effect profile is still being developed.

Future Prospects

The development of fenebrutinib represents an exciting new direction in MS treatment. If the ongoing clinical trials show positive results, fenebrutinib could potentially offer several advantages:

  • Oral administration: As a pill, it may be more convenient for patients compared to injections or infusions[1].
  • Targeted approach: By focusing on a specific enzyme (BTK), fenebrutinib may offer a more precise way of treating MS[2].
  • Potential for both RMS and PPMS: If successful, fenebrutinib could be one of the few treatments effective for both relapsing and primary progressive forms of MS[2][5].

However, it’s important to remember that fenebrutinib is still in the research phase. More data from ongoing and future clinical trials will be needed to fully understand its effectiveness and safety profile before it can be considered for approval as a treatment for multiple sclerosis.

Aspect Details
Drug Name Fenebrutinib (also known as RO7010939)
Administration Oral
Conditions Studied Relapsing Multiple Sclerosis (RMS), Primary Progressive Multiple Sclerosis (PPMS)
Trial Phases Phase I, Phase III
Comparators Placebo, Teriflunomide, Ocrelizumab
Primary Outcomes Annualized Relapse Rate, Time to Confirmed Disability Progression
Secondary Outcomes MRI lesion counts, Brain volume changes, Cognitive function, Patient-reported outcomes
Safety Assessments Adverse events, Laboratory tests, Vital signs, Physical examinations
Trial Durations Minimum of 96-120 weeks
Special Measures Double-blind, double-dummy design to maintain blinding

FAQ

  • What is fenebrutinib? Fenebrutinib is an investigational drug being studied for the treatment of multiple sclerosis. It is taken orally and is being evaluated for its potential to reduce disease activity and slow progression in both relapsing and primary progressive forms of MS.
  • How is fenebrutinib being tested in clinical trials? Fenebrutinib is being tested in several Phase III clinical trials. These studies compare fenebrutinib to existing MS treatments like teriflunomide and ocrelizumab, as well as to placebos. The trials measure various outcomes, including relapse rates, disability progression, brain lesions visible on MRI scans, and patient-reported quality of life measures.
  • What types of multiple sclerosis is fenebrutinib being studied for? Fenebrutinib is being studied for both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Different clinical trials are focusing on these specific types of MS to evaluate the drug's effectiveness in each form of the disease.
  • How long do the fenebrutinib clinical trials last? The duration of the fenebrutinib clinical trials varies, but many of them last for a minimum of 96 to 120 weeks (approximately 2 to 2.5 years). This extended period allows researchers to assess the long-term efficacy and safety of the drug.
  • What are some of the main outcomes being measured in these trials? The main outcomes being measured include annualized relapse rate, time to confirmed disability progression, changes in brain lesions as seen on MRI scans, brain volume changes, cognitive function tests, and patient-reported physical impacts of MS. The trials also closely monitor for any adverse events to assess the safety of fenebrutinib.

Ongoing Clinical Trials on Fenebrutinib

Unfortunately, we did not find any clinical trials matching the selected criteria. Try changing the filter settings or broadening the search criteria to see more available research participation opportunities.

Glossary

  • Fenebrutinib: An investigational oral drug being studied for the treatment of multiple sclerosis, aimed at reducing disease activity and slowing progression.
  • Multiple Sclerosis (MS): A chronic neurological disease that affects the central nervous system, causing a wide range of symptoms due to damage to nerve fibers.
  • Relapsing Multiple Sclerosis (RMS): A form of MS characterized by clearly defined attacks of new or increasing neurologic symptoms, followed by periods of partial or complete recovery.
  • Primary Progressive Multiple Sclerosis (PPMS): A type of MS characterized by worsening neurologic function from the onset of symptoms, without early relapses or remissions.
  • Magnetic Resonance Imaging (MRI): A medical imaging technique used to produce detailed images of the body's organs and tissues, particularly useful in detecting MS lesions in the brain and spinal cord.
  • Gadolinium-enhancing (Gd+) Lesions: Active MS lesions that can be seen on MRI scans after the injection of a contrast agent called gadolinium, indicating areas of current inflammation and blood-brain barrier breakdown.
  • T2-weighted Lesions: Areas of damage in the central nervous system visible on MRI scans, which may represent both old and new MS lesions.
  • Confirmed Disability Progression (CDP): A sustained increase in disability measured by standardized scales, typically confirmed over 12 or 24 weeks to ensure the progression is not due to temporary factors.
  • Annualized Relapse Rate (ARR): The average number of relapses a person with MS experiences per year, used as a measure of disease activity in clinical trials.
  • Symbol Digit Modality Test (SDMT): A cognitive test used to assess processing speed and working memory in people with MS, involving matching numbers to specific symbols within a time limit.
  • Neurofilament Light Chain (NfL): A protein released into the blood and cerebrospinal fluid when neurons are damaged, used as a biomarker for neurodegeneration in MS and other neurological conditions.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body, important for understanding the appropriate dosing and potential effects of a medication.
  • Open-Label Extension (OLE): A phase of a clinical trial where all participants receive the active study drug, often following the completion of the initial blinded study period.

References

  1. https://clinicaltrials.gov/study/NCT03596632
  2. https://clinicaltrials.gov/study/NCT05119569
  3. https://clinicaltrials.gov/study/NCT04586023
  4. https://clinicaltrials.gov/study/NCT04586010
  5. https://clinicaltrials.gov/study/NCT04544449